Prescription medication · GABA Analog (Alcohol Dependence)
acamprosate
Also sold as Campral. Acamprosate helps people who are alcohol-dependent to not drink alcohol.
Data updated 2026-05-15
- 299
- FDA reportsRarely reported
- 3
- InteractionsFew interactions
- $0.36
- Generic price (NADAC)
What the data shows
acamprosate (Campral) is a prescription GABA Analog (Alcohol Dependence), among the least-reported drugs the FDA tracks (299 FDA reports), with 3 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
acamprosate (Campral) is a prescription GABA Analog (Alcohol Dependence). Acamprosate helps people who are alcohol-dependent to not drink alcohol.
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.36/unit
Generic Available
Yes (4 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Acamprosate helps people who are alcohol-dependent to not drink alcohol.
Common side effects
Accidental injury, Weakness, Pain
Key warnings
Acamprosate may increase the risk of suicidal thoughts or actions.
The sections below are summarized in plain English from acamprosate's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Side Effects (from patient reports)
Based on 299 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for acamprosate, by number of reports
- Hypotension
Hypotension
14 reports
- Asthenia
Asthenia
13 reports
- Condition Aggravated
Condition Aggravated
13 reports
- Acute Kidney Injury
Acute Kidney Injury
12 reports
- Coma
Coma
12 reports
- Fatigue
Fatigue
11 reports
- Toxicity To Various Agents
Toxicity To Various Agents
11 reports
- Drug Abuse
Drug Abuse
10 reports
- Headache
Headache
10 reports
- Bradycardia
Bradycardia
9 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for acamprosate each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where acamprosate sits
acamprosate has more FDA adverse-event reports than 2% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is acamprosate; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 299 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2006–2025.
Total Reports
299
Reports Mentioning Death
25
8.4% of reports — not proof of cause
Hospitalization Reports
144
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | HYPOTENSION | 14 |
| 2 | ASTHENIA | 13 |
| 3 | CONDITION AGGRAVATED | 13 |
| 5 | ACUTE KIDNEY INJURY | 12 |
| 6 | COMA | 12 |
| 7 | FATIGUE | 11 |
| 8 | TOXICITY TO VARIOUS AGENTS | 11 |
| 9 | DRUG ABUSE | 10 |
| 10 | HEADACHE | 10 |
| 11 | BRADYCARDIA | 9 |
| 12 | CYTOLYTIC HEPATITIS | 9 |
| 13 | DEPRESSION | 9 |
| 14 | HEPATIC CYTOLYSIS | 9 |
| 15 | HYPOGLYCAEMIA | 9 |
| 16 | NEUTROPENIA | 9 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Known Drug Interactions
The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology (12.3) ].
Mechanism: Diazepam does not change the way your body absorbs or uses acamprosate. These drugs do not have a known interaction that affects their levels in the blood.
The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology (12.3) ].
Mechanism: These two drugs do not significantly change how the other works in your body.
The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology (12.3) ].
Mechanism: Disulfiram does not change the way your body breaks down or uses acamprosate.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
Can I drink alcohol while taking acamprosate?
What if I have kidney problems?
Will acamprosate cure my alcoholism?
How long will I need to take acamprosate?
Can I stop taking acamprosate suddenly?
Does acamprosate interact with other medications?
What should I do if I feel depressed or suicidal?
Can I drive or operate machinery while taking acamprosate?
What are the ingredients in acamprosate?
How should I dispose of unused acamprosate?
What are the common side effects of acamprosate?
Does acamprosate interact with other medications?
What drug class is acamprosate?
What pregnancy or breastfeeding source fields are listed for acamprosate?
Related Medications in GABA Analog (Alcohol Dependence)
Other drugs grouped near acamprosate - same-class peers and common alternatives.
alprazolam
Xanax
Alprazolam (Xanax) is a medication that can help you with anxiety and panic disorders.
Compare with acamprosate →
amitriptyline
Elavil
Amitriptyline is a medicine used to treat depression.
Compare with acamprosate →
amphetamine/dextroamphetamine
Adderall, Adderall XR
Adderall XR is a stimulant medicine.
Compare with acamprosate →
aripiprazole
Abilify
Aripiprazole (Abilify) is a medicine used to treat certain mental disorders and mood problems.
Compare with acamprosate →
asenapine
Saphris
Asenapine (Saphris) is an antipsychotic medicine.
Compare with acamprosate →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for acamprosate: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 299.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 8.36%.
- pramipexole Δ 0.01 pts · 14,399 reports · Dopamine Agonist 8.38%death share
- doxazosin Δ 0.03 pts · 27,049 reports · Alpha-1 Adrenergic Blocker 8.39%death share
- clindamycin Δ 0.03 pts · 27,449 reports · Lincosamide Antibiotic 8.33%death share
- lamotrigine Δ 0.04 pts · 127,196 reports · Anticonvulsant 8.40%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on acamprosate
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for acamprosate
The FDA label for acamprosate (sold under brand names such as Campral) classifies it as a prescription-only medication in the GABA Analog (Alcohol Dependence) class. Acamprosate helps people who are alcohol-dependent to not drink alcohol. Official labeling lists 15 commonly reported side effects, including Accidental injury, Weakness, Pain.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 299 voluntary reports. The database also lists 3 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS shows a generic unit cost of $0.36.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 6, 2023
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages